Bruton Limited (BRUT OL) stock market data APIs
kr54.3567
-0.59(-1.1%)
as of February 10, 2026
Try our APIs with
free plan!
Bruton Limited Financial Data Overview
Price chart is built with
Anychart
Bruton Limited, through its subsidiaries, owns and operates crude oil tankers. It also seeks to invest in the shipping, offshore, and energy sectors. The company was incorporated in 2023 and is based in Hamilton, Bermuda.
Prev. Close
54.3567
Open
53.7661
High
54.3893
Low
53.6468
52 wk Range
37.6-80
Market Cap
0
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Bruton Limited data using free add-ons & libraries
Get Bruton Limited Fundamental Data
Bruton Limited Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bruton Limited News
New
Jefferies Maintains Buy on Sanofi (SNY) Despite Regulatory Overhang
Sanofi (NASDAQ:SNY) is among the ridiculously cheap stocks to buy now. On December 28, Jefferies reiterated its ‘Buy’ rating on Sanofi (NASDAQ:SNY) with an unchanged price target of €100. This r...
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
If approved, sonrotoclax will become the first BCL2 inhibitor for R/R MCL in the U.S., addressing a high unmet need in an aggressive cancer Sonrotoclax previously received Breakthrough Therapy Design...
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
In the TRANSCEND MCL trial, 82.7% of patients responded to Breyanzi, with 71.6% of patients achieving complete response Breyanzi demonstrated sustained clinical benefit, with 50.8% of patients still ...
![[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis](/build/assets/fallback3-CioIYWIa.jpg)
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis
F. Hoffmann-La Roche Ltd The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide In a...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
